1. Home
  2. XPO vs ILMN Comparison

XPO vs ILMN Comparison

Compare XPO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPO Inc.

XPO

XPO Inc.

HOLD

Current Price

$143.24

Market Cap

16.4B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$128.82

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPO
ILMN
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
XPO
ILMN
Price
$143.24
$128.82
Analyst Decision
Strong Buy
Hold
Analyst Count
18
15
Target Price
$147.17
$114.93
AVG Volume (30 Days)
1.3M
1.5M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.78
4.46
Revenue
$8,068,000,000.00
$4,288,000,000.00
Revenue This Year
$1.59
N/A
Revenue Next Year
$3.74
$2.08
P/E Ratio
$51.41
$28.91
Revenue Growth
N/A
N/A
52 Week Low
$85.06
$68.70
52 Week High
$161.00
$153.06

Technical Indicators

Market Signals
Indicator
XPO
ILMN
Relative Strength Index (RSI) 58.19 66.70
Support Level $130.02 $124.27
Resistance Level $142.64 $129.72
Average True Range (ATR) 5.60 3.90
MACD 0.66 -0.41
Stochastic Oscillator 82.98 77.82

Price Performance

Historical Comparison
XPO
ILMN

About XPO XPO Inc.

Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: